Filing Analysis
Shattuck Labs, Inc. entered into an underwriting agreement on June 9, 2026, to sell 10,879,376 shares of common stock and 7,870,624 pre-funded warrants at a public offering price of approximately $4.00 per share. The underwriters also fully exercised an over-allotment option for an additional 2,812,500 shares on June 10, 2026.
🚩 Red Flags
- Significant dilution: The issuance of over 21 million potential shares (including warrants and over-allotment) will dilute existing shareholders.
- Use of pre-funded warrants often indicates that institutional investors are capping their ownership to avoid SEC beneficial ownership reporting requirements (5% threshold).
📋 Key Facts
- Offering price: $4.00 per share for common stock; $3.9999 per share for pre-funded warrants.
- Total common shares issued: 10,879,376 shares.
- Total pre-funded warrants issued: 7,870,624 shares.
- Underwriters' over-allotment option of 2,812,500 shares was exercised in full on June 10, 2026.
- Pre-funded warrants have a $0.0001 exercise price and are subject to beneficial ownership limits (4.99% or 9.99%).
- Expected closing date of the offering is June 11, 2026.
Shattuck Labs announced positive Phase 1 data for its lead candidate SL-325, demonstrating a favorable safety profile and low immunogenicity. The company also provided a timeline for its Phase 2b trial in Crohn's disease and reported significant proceeds from warrant exercises.
📋 Key Facts
- Phase 1 trial of SL-325 (n=72) showed complete DR3 occupancy at doses of 0.1 mg/kg and higher.
- Immunogenicity was low, with anti-drug antibodies (ADA) detected in only 3.7% (2/54) of participants.
- No serious treatment-emergent adverse events (TEAEs) were reported; all TRAEs were Grade 1.
- Initiation of RECEPTIVE-CD1 Phase 2b trial for Crohn's disease is expected in Q3 2026, with primary endpoint data expected in H1 2028.
- IND filing for bispecific candidate SL-846 is expected in the first half of 2027.
- The company expects to receive approximately $49.3 million in additional gross proceeds from the exercise of 45.4 million warrants.
Shattuck Labs, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as the auditor, and the approval of an amended 2020 Equity Incentive Plan.
📋 Key Facts
- Annual Meeting held on May 28, 2026.
- Stockholders approved the amendment and restatement of the 2020 Equity Incentive Plan, increasing available shares by 1,691,082 and extending the term to March 23, 2036.
- Director nominees Taylor Schreiber, Helen M. Boudreau, and Clay Siegall were elected.
- KPMG LLP was ratified as the independent auditor.
- Stockholders voted to maintain an annual frequency for advisory votes on executive compensation.
- As of April 2, 2026, there were 75,581,787 shares of common stock entitled to vote.
Shattuck Labs, Inc. reported its financial results for the first quarter ended March 31, 2026. The results were announced via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on May 7, 2026, to report financial results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Shattuck Labs, Inc. reported its financial results for the fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to the filing on March 5, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The report was signed by CEO Dr. Taylor Schreiber on March 5, 2026.